Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III (Q83571290)
Jump to navigation
Jump to search
scientific article published on 01 February 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III |
scientific article published on 01 February 2012 |
Statements
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial (English)
P P Tak
P J Mease
M C Genovese
J Kremer
B Haraoui
Y Tanaka
C O Bingham
A Ashrafzadeh
H Travers
S Safa-Leathers
S Kumar